Nevro

Traded on the St. Petersburg Stock Exchange
Nevro Corp is an American medical device company focused on providing products for patients suffering from debilitating chronic pain. The Company develops and commercializes a spinal cord stimulation system for the treatment of chronic pain. Nevro markets its products worldwide.
Nevro stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Nevro balance sheet

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Nevro cash flows

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Nevro multipliers

Report period2018 2019 2020 2021 20222023
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Nevro profitability

Report period2018 2019 2020 2021 20222023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Nevro assets
Nevro cash flows

Nevro dividend policy

The company doesn't provide dividend.

Nevro shares

TickerNameTypeNominal valueISINPrice
NVRO:USNevroCommon share-US64157F1030$5.606
Nevro news
24.02.2022
Nevro's GAAP loss for 2021 was $131.36 million, up 58.1% from $83.065 million in the prior year. Revenue increased 6.9% to $386.905 million from $362.048 million a year earlier.
Source: {source} pictogram nevro.com
Pictogram next
09.11.2021
Nevro's GAAP loss for 9M 2021 was $101.226 million, up 33.3% from $75.936 million in the prior year. Revenue increased 12.6% to $284.145 million from $252.317 million a year earlier.
Source: {source} pictogram nevro.com
Pictogram next
05.08.2021
Nevro's GAAP loss for 6 months of 2021 was $51.151 million, down 22.4% from $65.951 million in the previous year. Revenue increased 32.7% to $190.94 million from $143.857 million a year earlier.
Source: {source} pictogram nevro.com
Pictogram next
06.05.2021
Nevro's GAAP loss for three months of 2021 was $29.561 million, up 18.8% from $24.888 million in the previous year. Revenue increased 1.3% to $88.61 million from $87.467 million a year earlier.
Source: {source} pictogram nevro.com
Pictogram next
All Nevro news
General information
Company nameNevro
Tags#medtech
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment
Business address1800 BRIDGE PARKWAY REDWOOD CITY CA 94065 650-251-0005
Mailing address1800 BRIDGE PARKWAY REDWOOD CITY CA 94065
Websitewww.nevro.com
Information disclosurewww.sec.gov